Delivery Order HT942525D0009-HT942525F0237
Award Date
6/6/25
Potential Completion Date
9/5/25
Potential Value
$111K
Federal Agency
Defense Health Agency
Awardee
Mapp Biopharmaceutical, Inc.
Ultimate Awardee
Not listed
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Definitive Contract awarded to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California, by the Defense Health Agency, a component of the U.S. Department of Defense. The contract has a ceiling value of $1,192,803.19 and is for the BASE YEAR of the MACV Contract, which generates MACV IGG2. The contract is a Firm Fixed Price arrangement with a period of performance through March 1, 2025. There was no set-aside designation for this award. Mapp Biopharmaceutical...
This $38,243,034.02 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, which has no set-aside designation, is for the development of medical countermeasures through planned clinical trials and outbreak preparedness. This contract builds on...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The firm-fixed-price purchase order, with a potential value of $149,998.71, is for research and development efforts related to STTR Phase I work. Mapp Biopharmaceutical has extensive experience providing therapeutic interventions and medical...
This is a $906,651,397.58 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Mapp Biopharmaceutical, Inc., a for-profit biotechnology company based in San Diego, California. The contract is for the procurement of therapeutics for Ebola, Sudan, and Marburg viruses, with a period of performance running through September 29, 2032. This contract has no set-aside designation. Mapp Biopharmaceutical is...
This is a cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract, which has a potential value of $7,486,450.79, is for an expanded access protocol for the drug ZMapp to treat viral hemorrhagic fevers like Ebola, Marburg, and Lassa. Mapp Biopharmaceutical is a prime contractor for ASPR, having...
This is a cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc. for the development of Mapp's therapeutic intervention MBP091 as an immunotherapy for the treatment of Marburg virus infection. The contract has a ceiling value of $299,045,139.03 and a completion date of July 31, 2036. No set-aside was used for this award. Mapp Biopharmaceutical is a biotechnology company that specializes in developing...
This is a $30,920,844.79 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract is for an Expanded Access Protocol for ZMapp, a medical countermeasure against the Ebola virus. This appears to be a follow-on to a previous contract (75A50122C00061) with Mapp Biopharmaceutical. The contract has no set-aside designation and is focused on advancing...
This is a $30,559,760.00 cost-plus-fixed-fee delivery order awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Manufacturing Operations Baltimore LLC, a for-profit manufacturer of medical countermeasures. The contract is for the development of the MAPP biopharmaceutical Viral Hemorrhagic Fever (VHF) Medical Countermeasure (MCM) platform. This work is being performed under the Centers for Innovation in...
Mapp Biopharmaceutical, Inc. has been awarded a definitive cost-plus-fixed-fee contract valued at $1.5 million by the U.S. Army's Research, Development and Engineering Command (RDECOM) to continue research under the Small Business Technology Transfer (STTR) Phase II program. The contract is for continued research and development originally solicited through the STTR mechanism. Performance will take place in San Diego, California over a period of thirty-three months concluding in February 2023....
The U.S. Defense Health Agency awarded a $180,000 firm-fixed-price purchase order to Genovac Antibody Discovery LLC, a self-certified small disadvantaged business, for the development and testing of human monoclonal antibodies (mAbs). The contract, which does not have a set-aside designation, is in support of the Walter Reed Army Institute of Research (WRAIR) and Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS). The objectives are to perform feasibility studies for the...